Clinical Characteristics as Predictors of Response to Fluvoxamine, Paroxetine and Milnacipran in Patients with Depression

Abstract

The advent of the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin noradrenaline reuptake inhibitors (SNRIs) has been welcomed by patients, largely owing to their superior tolerability profile as compared to older antidepressants. However, individual SSRIs and SNRIs do not have the same effect on all patients all the time. The characteristics of fluvoxamine, paroxetine, and milnacipran used for the treatment of depression are reviewed in this paper. Fluvoxamine, paroxetine, and milnacipran each have their own optimal doses and appropriate treatment durations. Gender, age, first episode or recurrence, family history, psychiatric symptoms, and manic change rate were considered as predictors of the response to fluvoxamine, paroxetine, and milnacipran. Fluvoxamine showed a good response in young adults and in those with a first episode. Paroxetine showed a good response in first episode patients. Milnacipran showed a good response in older patients, males, first episode patients, and those with agitated depression. Paroxetine use was associated with a higher rate of mania induction than fluvoxamine and milnacipran. Knowing these characteristics should help guide clinicians in selecting antidepressants for their patients with depression.

Effect of Micronutrients on Behavior and Mood in Adults With ADHD: Evidence From an 8-Week Open Label Trial With Natural Extension

“…The treatment had also remarkably few side effects in comparison to many of the antidepressant and stimulant regimes. For example, although there were only a few participants who had a history of manic symptoms, the treatment did not activate mania in them or any other participants, a concern for some antidepressants (Morishita & Arita, 2005).…”

Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression

“…Given their popularity and widespread use, however, most contemporary research has focused on the newer generation serotonin reuptake inhibitors (SRIs) (3,(9)(10)(11)(12)(13). By contrast, other newer generation non-SRI antidepressant drugs have not been widely investigated in predictor studies (12,14,15).…”